Assessment of the immunogenicity and protective efficiency of a novel dual-promoter DNA vaccine, harboring SAG1 and GRA7 genes, from RH strain of Toxoplasma gondii in BALB/c mice

References

• Dubey JP. History of the discovery of the life cycle of Toxoplasma gondii. Int J Parasitol. 2009;39(8):877–882. doi:10.1016/j.ijpara.2009.02.01819630138
   PubMed Web of Science ®Google Scholar
• Robert-Gangneux F, Darde ML. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev. 2012;25(2):264–296.22491772
   PubMed Web of Science ®Google Scholar
• Awan KJ. Congenital toxoplasmosis: chances of occurrence in subsequent siblings. Ann Ophthalmol. 1978;10(4):459–465.677631
   PubMedGoogle Scholar
• Montoya JG, Remington JS. Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis. 2008;47(4):554–566. doi:10.1086/59014918624630
   PubMed Web of Science ®Google Scholar
• Pereira-Chioccola VL, Vidal JE, Su C. Toxoplasma gondii infection and cerebral toxoplasmosis in HIV-infected patients. Future Microbiol. 2009;4(10):1363–1379. doi:10.2217/fmb.09.8919995194
   PubMed Web of Science ®Google Scholar
• Lautenslager JP. Toxoplasmosis as a significant disease in man and animals with special reference to preventive measures by the farm community. Can Vet J. 1987;28(5):261–264.17422774
   PubMed Web of Science ®Google Scholar
• Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int J Parasitol. 2000;30(12–13):1217–1258.11113252
   PubMed Web of Science ®Google Scholar
• Rodriguez JB, Szajnman SH. New antibacterials for the treatment of toxoplasmosis; a patent review. Expert Opin Ther Pat. 2012;22(3):311–333. doi:10.1517/13543776.2012.66888622404108
   PubMed Web of Science ®Google Scholar
• Caetano BC, Bruna-Romero O, Fux B, Mendes EA, Penido ML, Gazzinelli RT. Vaccination with replication-deficient recombinant adenoviruses encoding the main surface antigens of Toxoplasma gondii induces immune response and protection against infection in mice. Hum Gene Ther. 2006;17(4):415–426. doi:10.1089/hum.2006.17.41516610929
   PubMed Web of Science ®Google Scholar
• Wang HL, Wang YJ, Pei YJ, et al. DNA vaccination with a gene encoding Toxoplasma gondii Rhoptry Protein 17 induces partial protective immunity against lethal challenge in mice. Parasite. 2016;23:4. doi:10.1051/parasite/201600426842927
   PubMedGoogle Scholar
• Zhang NZ, Chen J, Wang M, Petersen E, Zhu XQ. Vaccines against Toxoplasma gondii: new developments and perspectives. Expert Rev Vaccines. 2013;12(11):1287–1299. doi:10.1586/14760584.2013.84465224093877
   PubMed Web of Science ®Google Scholar
• Kur J, Holec-Ga̧sior L, Hiszczyńska-Sawicka E. Current status of toxoplasmosis vaccine development. Expert Rev Vaccines. 2009;8(6):791–808. doi:10.1586/erv.09.2719485758
   PubMed Web of Science ®Google Scholar
• Wang Y, Yin H. Research progress on surface antigen 1 (SAG1) of Toxoplasma gondii. Parasites Vectors. 2014;7(1):180–189. doi:10.1186/1756-3305-7-2324726014
   PubMed Web of Science ®Google Scholar
• Cesbron-Delauw MF, Gendrin C, Travier L, Ruffiot P, Mercier C. Apicomplexa in mammalian cells: trafficking to the parasitophorous vacuole. Traffic. 2008;9(5):657–664. doi:10.1111/j.1600-0854.2008.00728.x18315533
   PubMed Web of Science ®Google Scholar
• Bai M, Wang JL, Elsheikha HM, et al. Functional characterization of dense granule proteins in Toxoplasma gondii RH strain using CRISPR-Cas9 system. Front Cell Infect Microbiol. 2018;8:300–308. doi:10.3389/fcimb.2018.0002630211128
   PubMed Web of Science ®Google Scholar
• Hiszczyńska-Sawicka E, Oledzka G, Holec-Gasior L, et al. Evaluation of immune responses in sheep induced by DNA immunization with genes encoding GRA1, GRA4, GRA6 and GRA7 antigens of Toxoplasma gondii. Vet Parasitol. 2011;177(3–4):281–289. doi:10.1016/j.vetpar.2010.11.04721251760
   PubMed Web of Science ®Google Scholar
• Min J, Qu D, Li C, et al. Enhancement of protective immune responses induced by Toxoplasma gondii dense granule antigen 7 (GRA7) against toxoplasmosis in mice using a prime-boost vaccination strategy. Vaccine. 2012;30(38):5631–5636. doi:10.1016/j.vaccine.2012.06.08122789504
   PubMed Web of Science ®Google Scholar
• Neudecka A, Stachelhausa S, Nischika N, et al. Expression variance, biochemical and immunological properties of Toxoplasma gondii dense granule protein GRA7. Microbes Infect. 2002;4(6):581–590. doi:10.1016/S1286-4579(02)01576-912048027
   PubMed Web of Science ®Google Scholar
• Jongert E, Roberts CW, Gargano N, Förster-Wald E, Petersen E. Vaccines against Toxoplasma gondii: challenges and opportunities. Mem Inst Oswaldo Cruz. 2009;104(2):252–266. doi:10.1590/S0074-02762009000200019
   PubMed Web of Science ®Google Scholar
• Buxton D, Thomson K, Maley S, Wright S, Bos HJ. Vaccination of sheep with a live incomplete strain (S48) of Toxoplasma gondii and their immunity to challenge when pregnant. Vet Rec. 1991;129(5):89–93. doi:10.1136/vr.129.5.891926725
   PubMed Web of Science ®Google Scholar
• Saha R, Killian S, Donofrio RS. DNA vaccines: a mini review. Recent Patents DNA Gene Sequences. 2011;5(2):92–96. doi:10.2174/187221511796392114
   Google Scholar
• Roman M, Martin-Orozco E, Goodman JS, et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med. 1997;3(8):849–854.9256274
   PubMed Web of Science ®Google Scholar
• Lipford GB, Bauer M, Blank C, Reiter R, Wagner H, Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol. 1997;27(9):2340–2344. doi:10.1002/(ISSN)1521-41419341778
   PubMed Web of Science ®Google Scholar
• Klinman DM. Adjuvant activity of CpG oligodeoxynucleotides. Int Rev Immunol. 2006;25(3–4):135–154. doi:10.1080/0883018060074305716818369
   PubMed Web of Science ®Google Scholar
• Teimouri A, Azami SJ, Keshavarz H, et al. Anti-Toxoplasma activity of various molecular weights and concentrations of chitosan nanoparticles on tachyzoites of RH strain. Int J Nanomedicine. 2018;13:1341–1351. doi:10.2147/IJN.S17762729563791
   PubMed Web of Science ®Google Scholar
• Ayazian Mavi S, Keshavarz H, Modarresi M, et al. Design of a dual-promoter expression vector harboring Sag1 and Gra7 genes from Toxoplasma gondii (RH strain). Trop Biomed. 2018;35(1):126–134.
   Web of Science ®Google Scholar
• Wang H, He S, Yao Y, et al. Toxoplasma gondii: protective effect of an intranasal SAG1 and MIC4 DNA vaccine in mice. Exp Parasitol. 2009;122(3):226–232. doi:10.1016/j.exppara.2009.04.00219366622
   PubMed Web of Science ®Google Scholar
• Fletcher RH, Fletcher SW, Wagner EH. Clinical Epidemiology: The Essentials. 3rd ed. Baltimore: Williams and Wilkins; 1996.
   Google Scholar
• Coban C, Koyama S, Takeshita F, Akira S, Ishii KJ. Molecular and cellular mechanisms of DNA vaccines. Hum Vaccin. 2008;4(6):453–457. doi:10.4161/hv.4.1.480618535407
   PubMed Web of Science ®Google Scholar
• Wen Y, Wang CT, Ma TT, et al. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci. 2010;101(11):2325–2332. doi:10.1111/j.1349-7006.2010.01605.x20804499
   PubMed Web of Science ®Google Scholar
• Ma J, Trop S, Baer S, et al. Dynamics of the major histocompatibility complex class i processing and presentation pathway in the course of malaria parasite development in human hepatocytes: implications for vaccine development. PLoS One. 2013;8(9):e75321. doi:10.1371/journal.pone.007532124086507
   PubMed Web of Science ®Google Scholar
• Liu S, Shi L, Cheng YB, Fan GX, Ren HX, Yuan YK. Evaluation of protective effect of multi-epitope DNA vaccine encoding six antigen segments of Toxoplasma gondii in mice. Parasitol Res. 2009;105(1):267–274. doi:10.1007/s00436-009-1393-119288132
   PubMed Web of Science ®Google Scholar
• Hammouda NA, Abo el-Naga I, Hussein ED, Rashwan EA. Opsonization and intracellular killing of Toxoplasma gondii by human mononuclear phagocytes. J Egypt Soc Parasitol. 1995;25(1):11–17.7602153
   PubMedGoogle Scholar
• Vercammen M, Scorza T, El Bouhdidi A, et al. Opsonization of Toxoplasma gondii tachyzoites with nonspecific immunoglobulins promotes their phagocytosis by macrophages and inhibits their proliferation in nonphagocytic cells in tissue culture. Parasite Immunol. 1999;21(11):555–563.10583856
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Feldman HA. Identification of the activator system for antibody to toxoplasma as the classical complement pathway. J Infect Dis. 1980;141(3):366–369. doi:10.1093/infdis/141.3.3667365285
   PubMed Web of Science ®Google Scholar
• Ismail N, Olano JP, Feng HM, Walker DH. Current status of immune mechanisms of killing of intracellular microorganisms. FEMS Microbiol Lett. 2002;207(2):111–120. doi:10.1111/j.1574-6968.2002.tb11038.x11958927
   PubMed Web of Science ®Google Scholar
• Jongert E, Lemiere A, Van Ginderachter J, De Craeye S, Huygen K, D’Souza S. Functional characterization of in vivo effector CD4+ and CD8+ T Lymphocyte responses in acute Toxoplasmosis: an interplay of IFN-γ and cytolytic T cells. Vaccine. 2010;28(13):2556–2564. doi:10.1016/j.vaccine.2010.01.03120117266
   PubMed Web of Science ®Google Scholar
• Yarovinsky F. Innate immunity to Toxoplasma gondii infection. Nat Rev Immunol. 2014;14(2):109–121. doi:10.1038/nri359824457485
   PubMed Web of Science ®Google Scholar
• Dupont CD, Christian DA, Hunter CA. Immune response and immunopathology during toxoplasmosis. Semin Immunopathol. 2012;34(6):793–813. doi:10.1007/s00281-012-0339-322955326
   PubMed Web of Science ®Google Scholar
• Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. J Immunol. 2008;180(9):5771–5777. doi:10.4049/jimmunol.180.9.577118424693
   PubMed Web of Science ®Google Scholar
• Meng M, Zhou A, Lu G, et al. DNA prime and peptide boost immunization protocol encoding the Toxoplasma gondii GRA4 induces strong protective immunity in BALB/c mice. BMC Infect Dis. 2013;13(1):494–503. doi:10.1186/1471-2334-13-49424148219
   PubMed Web of Science ®Google Scholar
• Ching XT, Fong MY, Lau YL. Evaluation of immunoprotection conferred by the subunit vaccines of GRA2 and GRA5 against acute toxoplasmosis in BALB/c mice. Front Microbiol. 2016;7:609–619. doi:10.3389/fmicb.2016.0060927199938
   PubMed Web of Science ®Google Scholar
• Liu Q, Wang F, Wang G, et al. Toxoplasma gondii: immune response and protective efficacy induced by ROP16/GRA7 multicomponent DNA vaccine with a genetic adjuvant B7-2. Hum Vaccin Immunother. 2014;10(1):184–191. doi:10.4161/hv.2670324096573
   PubMed Web of Science ®Google Scholar
• Zhou H, Min J, Zhao Q, et al. Protective immune response against Toxoplasma gondii elicited by a recombinant DNA vaccine with a novel genetic adjuvant. Vaccine. 2012;30(10):1800–1806. doi:10.1016/j.vaccine.2012.01.00422240340
   PubMed Web of Science ®Google Scholar
• Zhu W, Wanga JL, Chena K, et al. Evaluation of protective immunity induced by DNA vaccination with genes encoding Toxoplasma gondii GRA17 and GRA23 against acute toxoplasmosis in mice. Exp Parasitol. 2017;179:20–27. doi:10.1016/j.exppara.2017.06.00228625894
   PubMed Web of Science ®Google Scholar
• Fang R, Feng H, Hu M, et al. Evaluation of immune responses induced by SAG1 and MIC3 vaccine cocktails against Toxoplasma gondii. Vet Parasitol. 2012;187(1–2):140–146. doi:10.1016/j.vetpar.2011.12.00722336771
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Horner AA, Takabayashi K, et al. Immunostimulatory DNA prepriming: a novel approach for prolonged Th1-biased immunity. Cell Immunol. 1999;198(1):69–75. doi:10.1006/cimm.1999.157210612653
   PubMed Web of Science ®Google Scholar
• Krieg AM. Immune effects and mechanisms of action of CpG motifs. Vaccine. 2000;19(6):618–622. doi:10.1016/S0264-410X(00)00249-811090712
   PubMed Web of Science ®Google Scholar
• Kojima Y, Xin KQ, Ooki T, et al. Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine. Vaccine. 2002;20(23–24):2857–2865. doi:10.1016/S0264-410X(02)00238-412126895
   PubMed Web of Science ®Google Scholar
• Jiang M, Yao J, Feng G. Protective effect of DNA vaccine encoding pseudomonas exotoxin A and PcrV against acute pulmonary P. aeruginosa infection. PLoS One. 2014;9(5):e96609. doi:10.1371/journal.pone.009660924788626
   PubMed Web of Science ®Google Scholar
• Askew D, Chu RS, Krieg AM, Harding CV. CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms. J Immunol. 2000;165(12):6889–6895. doi:10.4049/jimmunol.165.12.688911120813
   PubMed Web of Science ®Google Scholar
• Klinman DM, Klaschik S, Sato T, Tross D. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv Drug Deliv Rev. 2009;61(3):248–255. doi:10.1016/j.addr.2008.12.01219272313
   PubMed Web of Science ®Google Scholar